SEATTLE — In this Healio Video Perspective from the ARVO meeting, Sean D. Adrean, MD, discusses data on aflibercept 8 mg vs. aflibercept 2 mg for the treatment of diabetic macular edema at 1 year.
The post hoc analysis used data from the phase 2/3 PHOTON trial and investigated the impact of each aflibercept dose on vision and central retinal thickness in patients with a baseline best corrected visual acuity of 20/50 or worse or 20/40 or better.
“It was excellent to see that patients with the 8 mg aflibercept (Read more...)